Trials / Terminated
TerminatedNCT00576667
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-diabetic Patients With Nonalcoholic Steatohepatitis (NASH)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of Rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH).
Detailed description
The total duration per patient will be approximately 28 months including a 24-month double-blind treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimonabant | Tablet, oral administration |
| DRUG | Placebo (for Rimonabant) | Tablet, oral administration |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2007-12-19
- Last updated
- 2016-05-18
Locations
24 sites across 24 countries: United States, Argentina, Australia, Belgium, Brazil, Chile, China, Colombia, Croatia, France, Germany, Hungary, Italy, Malaysia, Mexico, Philippines, Poland, Portugal, Puerto Rico, Romania, Spain, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00576667. Inclusion in this directory is not an endorsement.